Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Histone 3 Methyltransferase (EZH2) Inhibition Enhances TRAIL-Induced Apoptosis In Mantle Cell Lymphoma Cells By Accelerated cFLIP Degradation

Frank K Braun, PhD, Rohit Mathur, PhD, Lalit Sehgal, Ph.D, Zuzana Berkova, PhD, Felipe Samaniego, M.D., M.P.H

Blood (2013) 122 (21): 4425.

https://doi.org/10.1182/blood.V122.21.4425.4425

Published: 2013

Journal Articles

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

Felipe Samaniego, M.D., M.P.H, Jorge E Romaguera, MD, Nathan Fowler, MD, Michelle A. Fanale, MD, Jatin J. Shah, M.D., Peter McLaughlin, MD, Barbara Pro, MD, Vijairam Selvaraj, MD, Frank K Braun, PhD, Rohit Mathur, PhD, Lei Feng, M.S., Sattva Neelapu, MD, Larry W. Kwak, MD, PhD

Blood (2013) 122 (21): 3039.

https://doi.org/10.1182/blood.V122.21.3039.3039

Published: 2013

Journal Articles

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

Lalit Sehgal, Ph.D, Frank K Braun, PhD, Rohit Mathur, PhD, Sattva Neelapu, MD, Larry W. Kwak, MD, PhD, Zuzana Berkova, PhD, Felipe Samaniego, M.D., M.P.H

Blood (2013) 122 (21): 5051.

https://doi.org/10.1182/blood.V122.21.5051.5051

Published: 2013

Journal Articles

CD74 Interferes With The Expression Of Fas Receptor On The Cell Surface

Zuzana Berkova, PhD, Xue Ao, MS, Frank K Braun, PhD, Jillian F Wise, B.S., Lalit Sehgal, Ph.D, Felipe Samaniego, M.D., M.P.H

Blood (2013) 122 (21): 4263.

https://doi.org/10.1182/blood.V122.21.4263.4263

Published: 2013

Journal Articles

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Sheeba K. Thomas, M.D., Tamara M Haygood, M.D., Muzaffar H. Qazilbash, MD, A. Georgina Melendez, M.D., Roxana Galvis, Kay B Delasalle, B.S., Lei Feng, M.S., Tiffany A. Richards, M.S., Felipe Samaniego, M.D., M.P.H, Luhua Wang, M.D., Jatin J. Shah, M.D., Robert Z. Orlowski, M.D., Ph.D., Donna M. Weber, M.D.

Blood (2013) 122 (21): 4396.

https://doi.org/10.1182/blood.V122.21.4396.4396

Published: 2013

Journal Articles

Double Hit Lymphoma: M.D. Anderson Experience

Yasuhiro Oki, MD, Mansoor Noorani, Richard Eric Davis, MD, Sattva S. Neelapu, MD, Alma Rodriguez, M.D., Fredrick B Hagemeister, MD, Nathan Fowler, MD, Michael Wang, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Bouthaina S. Dabaja, MD, Chelsea Pinnix, M.D., Larry W. Kwak, MD, PhD, Jorge E Romaguera, MD, Issa Khouri, MD, Jason R. Westin, MD, Luis E Fayad

Blood (2013) 122 (21): 1776.

https://doi.org/10.1182/blood.V122.21.1776.1776

Published: 2013

Journal Articles

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Jorge E Romaguera, MD, Michelle A. Fanale, MD, Felipe Samaniego, M.D., M.P.H, Luis E Fayad, Fredrick B Hagemeister, MD, Peter McLaughlin, MD, Maria Alma Rodriguez, MD, Pam Weaver, Kim Hartig, Maria Badillo, BS, Larry W. Kwak, MD, PhD, Anas Younes, MD, Barbara Pro, MD, Michael Wang, MD

Blood (2013) 122 (21): 5122.

https://doi.org/10.1182/blood.V122.21.5122.5122

Published: 2013

Journal Articles

Mechanism of Regulating Fas Signaling by Promyelocytic Leukemia Protein (PML) and Its Dominant-Negative Mutant PMLRARα

Rong-Hua Tao, M.D., Ph.D., Zuzana Berkova, PhD, Jillian F Wise, B.S., Haifeng Zhu, Ph.D., Xue Ao, MS, Zeming Chen, PhD, Wenzhuo Zhuang, PhD, Frank K Braun, PhD, Rohit Mathur, PhD, Felipe Samaniego, M.D.

Blood (2012) 120 (21): 1327.

https://doi.org/10.1182/blood.V120.21.1327.1327

Published: 2012

Journal Articles

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Yasuhiro Oki, MD, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, F.B. Hagemeister, MD, Peter McLaughlin, MD, Larry W. Kwak, MD, PhD, Jorge Enrique Romaguera, Michelle Fanale, MD, Anas Younes, MD, Maria A. Rodriguez, MD, Robert Z. Orlowski, MD, PhD, Michael Wang, M.D., Souzanne T Ouzounian, Felipe Samaniego, M.D., Luis Fayad, MD

Blood (2012) 120 (21): 3707.

https://doi.org/10.1182/blood.V120.21.3707.3707

Published: 2012

Journal Articles

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Jason R. Westin, MD, Fuliang Chu, PhD, Luis E Fayad, MD, Larry W Kwak, MD, PhD, Nathan H Fowler, MD, Jorge E Romaguera, MD, F.B. Hagemeister, MD, Michelle Fanale, MD, Felipe Samaniego, M.D., Rochelle Allen, RN, Lei Feng, Ph.D, Veerabhadran Baladandayuthapani, PhD, Rinat Rotem-Yehudar, PhD, Sattva Neelapu, MD

Blood (2012) 120 (21): 793.

https://doi.org/10.1182/blood.V120.21.793.793

Published: 2012

Journal Articles

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

Seema Rawal, PhD, Nathan Fowler, MD, Min Zhang, Ph.D., Zhiqiang Wang, Ph.D., Tariq Muzzafar, MBBS, Nusrat Harun, MS, Veerabhadran Baladandayuthapani, Ph.D., Rakesh Sharma, Ph.D, David Delgado, Michael Wallace, MD, Carla Heise, PhD, Linda Catherine Lacerte, RN, Felipe Samaniego, M.D., R Eric Davis, M.D, Sattva S. Neelapu, MD

Blood (2012) 120 (21): 2766.

https://doi.org/10.1182/blood.V120.21.2766.2766

Published: 2012

Journal Articles

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Nathan Fowler, M.D., Peter McLaughlin, M.D., Fredrick B. Hagemeister, M.D., Larry Kwak, M.D., Ph.D., Michelle Fanale, M.D., Sattva Neelapu, M.D., Luis Fayad, M.D., Barbara Pro, M.D., Crystal Sergent, RN, MSN, Shana R. S. White, B.S., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 1714.

https://doi.org/10.1182/blood.V114.22.1714.1714

Published: 2009

Journal Articles

Promyelocytic Leukemia-Retinoic Acid Receptor α Binds and Prevents Activation of the Fas Receptor and Suppresses Fas-Mediated Apoptosis.

Rong-Hua Tao, M.D., Ph.D., Zuzana Berkova, Ph.D., Jillian Wise, B.S., Urszula Daniluk, M.D., Ph.D., Felipe Samaniego, M.D.

Blood (2009) 114 (22): 3976.

https://doi.org/10.1182/blood.V114.22.3976.3976

Published: 2009

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Journal Articles

CD74 Is a Regulator of Fas-Mediated Apoptotic Signaling

Zuzana Berkova, Ph.D., Shu Wang, M.D., Jillian Wise, BS, Suizhao Wang, M.D., Ph.D., Ronghua Tao, Ph.D., Hoyoung Maeng, M.D., David Hawke, Ph.D., Larry W. Kwak, M.D., Ph.D., Felipe Samaniego, M.D.

Blood (2008) 112 (11): 2826.

https://doi.org/10.1182/blood.V112.11.2826.2826

Published: 2008

Journal Articles

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Michelle A. Fanale, M.D., Luis E. Fayad, M.D., Barbara Pro, M.D., Felipe Samaniego, M.D., Gracy Zachariah, R.N., Cesar A. Nunez, M.D., Yuan Ji, Ph.D., Anas Younes, M.D.

Blood (2008) 112 (11): 3048.

https://doi.org/10.1182/blood.V112.11.3048.3048

Published: 2008

Journal Articles

Human Herpesvirus 8 Protein K1 Interferes with Fas-Mediated Apoptosis Induces Clonal Growth and Lymphoid Hyperplasia

Ronghua Tao, M.D., Ph.D., Zuzana Berkova, Ph.D., Shu Wang, M.D., Suizhao Wang, M.D., Ph.D., Jillian Wise, BS, Hoyoung Maeng, M.D., Felipe Samaniego, M.D.

Blood (2008) 112 (11): 3773.

https://doi.org/10.1182/blood.V112.11.3773.3773

Published: 2008

Journal Articles

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D., Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D., Larry W. Kwak, M.D., Ph.D

Blood (2008) 112 (11): 835.

https://doi.org/10.1182/blood.V112.11.835.835

Published: 2008

Journal Articles

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Jorge Enrique Romaguera, MD, Luis Fayad, M.D., Maria Alma Rodriguez, M.D., F.B. Hagemeister, M.D., Barbara Pro, M.D., Peter McLaughlin, M.D., Anas Younes, M.D., Felipe Samaniego, M.D., Andre Goy, M.D., Andreas H. Sarris, M.D., Nam H. Dang, M.D., Luhua Wang, M.D., Hagop M. Kantarjian, M.D., Virginia Beasley, L. Jeffrey Medeiros, M.D., Ruth L. Katz, M.D., Fernando Cabanillas, M.D.

Blood (2006) 108 (11): 2749.

https://doi.org/10.1182/blood.V108.11.2749.2749

Published: 2006

Journal Articles

Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

Anas Younes, MD, Luis Y. Fayad, M.D., Andre Goy, M.D., Peter McLaughlin, M.D., Barbara Pro, M.D., Jorge Romaguera, M.D., Fredrick Hagemeister, M.D., Maria A. Rodriguez, M.D., Felipe Samaniego, M.D., Larry Kwak, M.D.Ph.D., Sattva Neelapu, M.D., L. Jeffrey Medeiros, M.D., Amanda Wedgwood, R.N., Michelle Fanale, M.D.

Blood (2006) 108 (11): 2742.

https://doi.org/10.1182/blood.V108.11.2742.2742

Published: 2006

NARROW

Histone 3 Methyltransferase (EZH2) Inhibition Enhances TRAIL-Induced Apoptosis In Mantle Cell Lymphoma Cells By Accelerated cFLIP Degradation

A Single Center Phase II Trial Of 90 yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease

FAS-AS1 Intronic Lncrna and Ibrutinib Negatively Regulate Soluble Fas Production and Sensitize B-Cell Lymphomas To Fas-Mediated Apoptosis

CD74 Interferes With The Expression Of Fas Receptor On The Cell Surface

A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM)

Double Hit Lymphoma: M.D. Anderson Experience

Phase II Trial Of Bortezomib In Combination With Fractionated Cyclophosphamide and Rituximab (BCR) For Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Mechanism of Regulating Fas Signaling by Promyelocytic Leukemia Protein (PML) and Its Dominant-Negative Mutant PMLRARα

R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma

Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma.

A Biologic Combination of Lenalidomide and Rituximab for Front-Line Therapy of Indolent B-Cell Non-Hodgkin's Lymphoma.

Promyelocytic Leukemia-Retinoic Acid Receptor α Binds and Prevents Activation of the Fas Receptor and Suppresses Fas-Mediated Apoptosis.

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

CD74 Is a Regulator of Fas-Mediated Apoptotic Signaling

A Phase I Study of Bortezomib in Combination with ICE (BICE) in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Human Herpesvirus 8 Protein K1 Interferes with Fas-Mediated Apoptosis Induces Clonal Growth and Lymphoid Hyperplasia

Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged Myelosuppression

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

Results of Rituximab Plus ABVD in 65 Newly Diagnosed Patients with Classical Hodgkin Lymphoma: Improvement of Event Free Survival (EFS) in All International Prognostic Score (IPS) Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only